MHC Hammer 揭示了癌症进化中的遗传性和非遗传性 HLA 破坏。
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
发表日期:2024 Oct 02
作者:
Clare Puttick, Thomas P Jones, Michelle M Leung, Felipe Galvez-Cancino, Jiali Liu, Manuel Varas-Godoy, Andrew Rowan, Oriol Pich, Carlos Martinez-Ruiz, Robert Bentham, Krijn K Dijkstra, James R M Black, Rachel Rosenthal, Nnennaya Kanu, Kevin Litchfield, Roberto Salgado, David A Moore, Peter Van Loo, Mariam Jamal-Hanjani, Sergio A Quezada, , Charles Swanton, Nicholas McGranahan
来源:
NATURE GENETICS
摘要:
I 类人类白细胞抗原 (HLA) 分子的破坏对于免疫逃避和肿瘤进化具有重要意义。我们开发了主要的组织相容性复合体杂合性缺失(LOH)、等位基因特异性突变以及表达和抑制的测量(MHC Hammer)。我们在正常肺和乳腺组织中发现了 HLA 等位基因表达的广泛变异性和普遍的 HLA 选择性剪接。在肺 TRACERx 以及肺和乳腺癌 TCGA 队列中,61% 的肺腺癌 (LUAD)、76% 的肺鳞状细胞癌 (LUSC) 和 35% 的雌激素受体阳性 (ER) 癌症具有 I 类 HLA 转录抑制,而 HLA肿瘤富集的选择性剪接发生在 31%、11% 和 15% 的 LUAD、LUSC 和 ER 癌症中。与 HLA 功能障碍在肿瘤进化中的重要性一致,在 LUAD 中,HLA LOH 与转移相关,并且接种转移的 LUAD 原发肿瘤区域比非接种区域具有更低的有效新抗原负荷。这些数据强调了 HLA 转录组破坏的程度和重要性,包括癌症进化中的抑制和选择性剪接。© 2024。作者。
Disruption of the class I human leukocyte antigen (HLA) molecules has important implications for immune evasion and tumor evolution. We developed major histocompatibility complex loss of heterozygosity (LOH), allele-specific mutation and measurement of expression and repression (MHC Hammer). We identified extensive variability in HLA allelic expression and pervasive HLA alternative splicing in normal lung and breast tissue. In lung TRACERx and lung and breast TCGA cohorts, 61% of lung adenocarcinoma (LUAD), 76% of lung squamous cell carcinoma (LUSC) and 35% of estrogen receptor-positive (ER+) cancers harbored class I HLA transcriptional repression, while HLA tumor-enriched alternative splicing occurred in 31%, 11% and 15% of LUAD, LUSC and ER+ cancers. Consistent with the importance of HLA dysfunction in tumor evolution, in LUADs, HLA LOH was associated with metastasis and LUAD primary tumor regions seeding a metastasis had a lower effective neoantigen burden than non-seeding regions. These data highlight the extent and importance of HLA transcriptomic disruption, including repression and alternative splicing in cancer evolution.© 2024. The Author(s).